Apomorphine pharmacokinetics in Parkinsonism after intranasal and subcutaneous application

@article{Sam2010ApomorphinePI,
  title={Apomorphine pharmacokinetics in Parkinsonism after intranasal and subcutaneous application},
  author={E. Sam and Anne P. Jeanjean and Jean-marie Maloteaux and Norbert Verbeke},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  year={2010},
  volume={20},
  pages={27-33}
}
SummaryApomorphine was administered subcutaneously and intranasally to 7 patients suffering from Parkinsonism with ‘on-off problems. This comparative pharmacokinetic study showed that the two routes of administration are comparable with respect to absorption kinetics. Apomorphine is rapidly absorbed when administered intranasally or subcutaneously with an absorption half life of 8.6 min and 5.8 min, respectively. The high rate of absorption is also reflected by the time for the plasma… 
Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061
TLDR
Findings indicate the potential utility of intranasal dosing as a route that circumvents the first-pass effects for PF-219061 resulting in high exposures and verified the preclinical predictions demonstrating rapid absorption and approximately dose-proportional increases in exposure.
Pharmacological Insights into the Use of Apomorphine in Parkinson’s Disease: Clinical Relevance
TLDR
The ongoing progress in the development of analytical methods should be accompanied by new pharmacokinetic and pharmacodynamic studies of apomorphine metabolism and sites of action in humans, as its biochemistry has yet to be fully described.
Effects of apomorphine on locomotive activity and monoamine metabolism: a dose related study.
TLDR
Monitoring dose dependent effects of apomorphicine on motor activity and monoamine metabolism could be helpful in elucidating the effect of apomorphine at different doses and its implication for extending therapeutics in Parkinson's and related disorders.
Preactivated thiomers for intranasal delivery of apomorphine: In vitro and in vivo evaluation.
TLDR
Because of the pronounced improvement among other polymers, PAA250-cys-2MNA with high degree of preactivation could be considered as promising excipient for nasal delivery of apomorphine.
ANTIEMETIC DRUGS AS A NASAL DRUG DELIVERY - A REVIEW
TLDR
The nasal mucosa has seriously emerged as a therapeutically viable route for the systemic drug delivery and promising results with enhanced bioavailability have been obtained upon nasal administration and have prompted more extensive investigations in this area.
131I-trazodone: preparation, quality control and in vivo biodistribution study by intranasal and intravenous routes as a hopeful brain imaging radiopharmaceutical.
TLDR
The biodistribution results showed a notably higher and sustained brain uptake for INME compared to IVS and INS at all time intervals, which could decrease the systemic side effects of trazodone.
Efficacy of oral lipid‐based formulations of apomorphine and its diester in a Parkinson's disease rat model
TLDR
Evaluation of the behavioural response of apomorphine and its prodrug administered in oral lipid‐based formulations in Parkinson's disease.
NASAL CAVITY, A PROMISING TRANSMUCOSAL PLATFORM FOR DRUG DELIVERY AND RESEARCH APPROACHES FROM NASAL TO BRAIN TARGETTING
TLDR
An anatomical, histological and physiological overview of nose, absorption enhancers, barriers related to nasal drug delivery, physicochemical, biological and formulation related factors affecting nasal drug Delivery system and its advantages is provided.
NASAL DRUG DELIVERY SYSTEM AN OVERVIEW
TLDR
An overview of intranasal drug delivery with its various aspects like factors affecting nasal absorption, strategies to improve bioavailability are discussed.
New non-oral drug delivery systems for Parkinson's disease treatment
TLDR
The long-term complications and limitations of LD treatment might be improved by changing therapy from the present pulsatile stimulation to a more constant stimulation of central dopamine receptors, with the aim of achieving long-lasting and less fluctuating drug levels, minimization of peak levels and thereby reduction of side effects.
...
1
2
3
...

References

SHOWING 1-10 OF 17 REFERENCES
Peripheral pharmacokinetics of apomorphine in humans
TLDR
It is concluded that apomorphine is rapidly and completely absorbed from subcutaneous tissue, correlating with the rapid onset of clinical effects, and that the brief duration of clinical action of the drug is explained by its rapid clearance.
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
TLDR
The results indicated that SL apomorphine can reduce severe off periods in parkinsonian patients when used chronically, and its long-term use is limited by a severe side effect (stomatitis).
Subcutaneous apomorphine in the treatment of Parkinson's disease.
TLDR
Subcutaneous apomorphine is proposed as an effective treatment for patients with incapacitating "off" period disabilities refractory to oral medication and should be considered before experimental implantation procedures.
SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS
TLDR
Results confirm that during off periods dopamine receptors remain responsive to stimulation and provide evidence of a new, effective, and well-tolerated treatment for the most disabling complication of long-term levodopa therapy.
Intranasal apomorphine in parkinsonian on-off fluctuations.
TLDR
The simplicity in the technique of intranasal apomorphine administration was found to be superior by all patients and the speed and the quality of motor response and the pharmacokinetic profile showed results similar to those seen after subcutaneous injection of apomorphicine administered by insulin pen syringe.
Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection.
TLDR
Dilute solutions of apomorphine in plasma are unstable at 37 degrees C and pH 7.4 and Mercaptoethanol (0.01%) is effective in stabilizing these samples while sodium metabisulphite (1%) is not effective.
Intranasal apomorphine: a new treatment in Parkinson's disease.
TLDR
The initial downward gaze palsy indicates a bilateral involvement of the upper mesencephalon, which can be compared to Wernicke's encephalopathy where hypothermia may occur, and where the mesodiencephalic lesions, although more extended rostro-caudally, are bilateral.
Rectal apomorphine: a new treatment modality in Parkinson's disease.
TLDR
The evidence suggests that this patient with Munchausen's syndrome has repeatedly been admitted to hospital for investigation of acute headache and left hemiparesis and has undergone repeated radiological investigations and lumbar puncture.
Subcutaneous apomorphine in Parkinson's disease.
TLDR
The clinical features, diagnostic procedures and results of surgical treatment in 68 patients of Paget's disease of bone and its response to calcitonin therapy are summarized.
Bioanalysis of apomorphine using HPLC - ECD
  • 1994
...
1
2
...